Physician profile
John E Moskaitis
NPI 1316042591
$1,820.93
in general payments reported to CMS, 2019-2025
26 companies · $391 in 2025
The $391 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $368 · 2021: $213 · 2022: $183 · 2023: $47.23 · 2024: $93.38 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $418.99 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $226.41 | 2019-2024 | Farxiga, Airsupra |
| Allergan, INC. | $179.59 | 2020 | |
| Pfizer INC. | $170.94 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $159.86 | 2019-2023 | Verquvo, Steglujan, Steglatro |
| Novartis Pharmaceuticals Corporation | $133.50 | 2019-2020 | |
| Novo Nordisk INC | $96.50 | 2019-2025 | |
| Lilly USA, LLC | $90.52 | 2022-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $34.74 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.18 | 2019-2023 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $25.15 | 2022 | |
| Inspire Medical Systems, INC. | $24.27 | 2024 | Inspire |
| Abbott Laboratories | $22.34 | 2021 | |
| Ibsa Pharma INC. | $21.83 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.68 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $18.03 | 2022 | |
| Medtronic, INC. | $17.34 | 2022 | |
| Scilex Pharmaceuticals INC. | $16.95 | 2019 | |
| Mylan Specialty L.P. | $16.61 | 2019 | |
| Amarin Pharma, INC. | $16.35 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.00 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.50 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.47 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.59 | 2020 | |
| Collegium Pharmaceutical, INC. | $14.29 | 2019 | |
| Eisai INC. | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Moskaitis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.